Literature DB >> 2719466

Effect of norfloxacin on theophylline metabolism.

R L Davis1, H W Kelly, R W Quenzer, J Standefer, B Steinberg, J Gallegos.   

Abstract

The purpose of this study was to investigate the effect of norfloxacin on theophylline elimination. Ten normal volunteers were studied. In a randomized crossover sequence, each subject received 6 mg of aminophylline per kg of body weight by a 30-min intravenous infusion on day 4 of taking norfloxacin (400 mg every 12 h) or while drug free. Mean theophylline clearance decreased and mean elimination half-life increased after norfloxacin administration (from 0.036 +/- 0.006 to 0.033 +/- 0.004 liter/h per kg and from 8.7 +/- 1.2 to 9.5 +/- 1.5 h, respectively; P less than 0.05, Wilcoxon signed-ranks test). We conclude that norfloxacin taken in recommended doses for 3 days has a small inhibitory effect on theophylline metabolism that would probably not cause clinically important elevations in theophylline concentrations in most patients.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2719466      PMCID: PMC171459          DOI: 10.1128/AAC.33.2.212

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  Pharmacokinetics of ofloxacin and theophylline alone and in combination.

Authors:  J B Fourtillan; J Granier; B Saint-Salvi; J Salmon; A Surjus; D Tremblay; M Vincent Du Laurier; S Beck
Journal:  Infection       Date:  1986       Impact factor: 3.553

2.  Quinolones and raised plasma concentrations of theophylline.

Authors:  F P Maesen; J P Teengs; C Baur; B I Davies
Journal:  Lancet       Date:  1984-09-01       Impact factor: 79.321

3.  Enoxacin raises plasma theophylline concentrations.

Authors:  W J Wijnands; C L van Herwaarden; T B Vree
Journal:  Lancet       Date:  1984-07-14       Impact factor: 79.321

4.  Noncompartmental determination of the steady-state volume of distribution for any mode of administration.

Authors:  D Perrier; M Mayersohn
Journal:  J Pharm Sci       Date:  1982-03       Impact factor: 3.534

5.  Serum and sputum concentrations of enoxacin after single oral dosing in a clinical and bacteriological study.

Authors:  B I Davies; F P Maesen; J P Teengs
Journal:  J Antimicrob Chemother       Date:  1984-09       Impact factor: 5.790

6.  Effect of norfloxacin on theophylline pharmacokinetics at steady state.

Authors:  S K Bowles; Z Popovski; M J Rybak; H B Beckman; D J Edwards
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

7.  Enoxacin decreases the clearance of theophylline in man.

Authors:  W J Wijnands; T B Vree; C L Van Herwaarden
Journal:  Br J Clin Pharmacol       Date:  1985-12       Impact factor: 4.335

8.  The influence of quinolone derivatives on theophylline clearance.

Authors:  W J Wijnands; T B Vree; C L van Herwaarden
Journal:  Br J Clin Pharmacol       Date:  1986-12       Impact factor: 4.335

9.  Enoxacin in lower respiratory tract infections.

Authors:  W J Wijnands; A J van Griethuysen; T B Vree; B Van Klingeren; C L van Herwaarden
Journal:  J Antimicrob Chemother       Date:  1986-12       Impact factor: 5.790

10.  Ranitidine at very large doses does not inhibit theophylline elimination.

Authors:  H W Kelly; J R Powell; J F Donohue
Journal:  Clin Pharmacol Ther       Date:  1986-05       Impact factor: 6.875

View more
  5 in total

1.  Effect of ciprofloxacin on antipyrine pharmacokinetics and metabolism in rats.

Authors:  A Anadón; M R Martinez-Larrañaga; M C Fernandez; M J Diaz; P Bringas
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

2.  Safety of fleroxacin coadministered with theophylline to young and elderly volunteers.

Authors:  M Parent; M St-Laurent; M LeBel
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

3.  Absence of effect of rufloxacin on theophylline pharmacokinetics in steady state.

Authors:  M Kinzig-Schippers; U Fuhr; M Cesana; C Müller; A H Staib; S Rietbrock; F Sörgel
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

Review 4.  Clinical pharmacokinetics of ciprofloxacin.

Authors:  K Vance-Bryan; D R Guay; J C Rotschafer
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

5.  Inhibitory potency of quinolone antibacterial agents against cytochrome P450IA2 activity in vivo and in vitro.

Authors:  U Fuhr; E M Anders; G Mahr; F Sörgel; A H Staib
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.